摘要
目的:通过口服低剂量抗原(rhβ2GP1)干预EAPS疾病进展过程中小鼠外周血CD4+CD25+Treg和Th17数量和功能变化,探讨EAPS口服耐受机制。方法:ELISA法检测小鼠外周血浆中IL-17、IL-2、IL-6、TGF-β水平变化;计算小鼠流产率(%)、活化部分凝血活酶时间(APTT)和血小板计数(PLT)判断APS病理改变;流式细胞术检测小鼠PBMC中CD4+CD25+Treg及Th17细胞变化。结果:与模型组相比,耐受组小鼠IL-17、IL-2、IL-6水平明显降低,APTT缩短,TGF-β、PLT升高,流产率降低,均差异显著(P<0.05);耐受组小鼠PBMC中CD4+CD25+Treg和Th17细胞百分率及两者的比率与模型组相比差异显著(P<0.05),而与对照组则无差异(P>0.05)。结论:CD4+CD25+Treg/Th17在EAPS口服耐受的诱导中发挥重要作用。
Objective: To explore the oral tolerance mechanism of experimental anti -phospholipid syndrome (EAPS) by interve- ning numerical and functional changes of CIM+ CD25+ regulatory T (Treg) and Thl7 in peripheral blood of mice in the course of EAPS pro- gression with oral administration of low- dose recombinant human 132 glycoprotein 1 (rhl3zGP1) . Methods: ELISA was used to detect the changes of interleukin - 17 ( IL - 17 ), interleukin - 2 ( IL - 2 ), interleukin - 6 ( IL - 6), and transforming growth factor - 13 ( TGF - 13) levels in peripheral plasma of mice; the abortion rate, activated partial thromboplastin time (AIYT), and platelet count (PLT) were calculated ; pathological changes of APS were judged ; flow cytometry was applied to detect the changes of CD4+ CD25 + Treg and Thl7 cells in pe- ripheral blood mononuclear cells. Results: Compared with model group, the levels of IL - 17, IL -2, and IL -6 in tolerance group decreased significantly (P 〈0. 05) , APTT shortened significantly (P 〈0. 05) , TGF - 13 level and PLT increased significantly (P 〈0. 05) , abortion rate decreased significantly ( P 〈 0. 05 ) ; there were statistically significant differences in the percentages of CD4+ CD25+ Treg and Thl7 cells and Treg/Thl7 ratio in peripheral blood mononuelear cells between tolerance group and model group (P 〈 0. 05 ) , compared with control group, there was no statistically significant difference (P 〉 0.05 ) . Conclusion: CD4+ CD25 + Treg/Th17 ratio plays an important role in induction of oral tolerance in EAPS.
出处
《中国妇幼保健》
CAS
2015年第10期1593-1595,共3页
Maternal and Child Health Care of China
基金
吉林省科技厅项目〔No.201015172〕
吉林省卫生计生委项目〔NO.20112074
NO.2010Z101-263〕